Showing results 241 to 260 of 1437
  Clinical en economic implications of non-adherence with osteoporosis medicationsHiligsmann, Mickaël  ; Rabenda, Véronique ; Gathon, Henry-Jean et alin Osteoporosis International (2009, March), 20(S1), 16 Detailed reference viewed: 29 (6 ULg)Cost-utility of strontium ranelate for the prevention and treatment of postmenopausal osteoporotic womenHiligsmann, Mickaël ; Bruyère, Olivier ; Reginster, Jean-Yves in Osteoporosis International (2009, March), 20(S1), 129 Detailed reference viewed: 14 (7 ULg)Cost-effectiveness of strontium ranelate versus intravenous ibandronate in the treatment of postmenopausal womenHiligsmann, Mickaël ; Neuprez, Audrey ; et alin Osteoporosis International (2009, March), 20(S1), 130 Detailed reference viewed: 46 (6 ULg)How does the efficacy of Protelos translate into patient benefits ?Reginster, Jean-Yves in Osteoporosis International (2009, March), 20(Suppl.1), 178 Detailed reference viewed: 26 (1 ULg)Fracture risk in women ≥ 65 years with once-monthly oral bisphosphonate compared with weekly bisphosphonates: subanalysis from the evaluation of ibandronate efficacy (VIBE) database study.; ; et al in Osteoporosis International (2009, March), 20(Suppl.1), 153 Detailed reference viewed: 5 (0 ULg)BEATRIS - Better adherence to treatment with ibandronate in osteoporosis: bone markers feedback study.; ; et al in Osteoporosis International (2009, March), 20(Suppl.1), 23 Detailed reference viewed: 13 (1 ULg)Prediction of spinal osteoarthritis progression by assessment of biochemical markers of bone and cartilage remodelling: a 3-year studyBruyère, Olivier ; Collette, Julien ; Deroisy, Rita et alin Osteoporosis International (2009, March), 20(Suppl.1), 8 Detailed reference viewed: 14 (7 ULg)FRAX(r) and the assessment of fracture probability in men and women from Belgium.Reginster, Jean-Yves ; ; Hiligsmann, Mickaël et alin Osteoporosis International (2009, March), 20(Suppl.1), 38-39 Detailed reference viewed: 12 (1 ULg)Efficacy of monthly oral ibandronate is maintained over 5 years: The MOBILE LTE study.; ; et al in Osteoporosis International (2009, March), 20(Suppl.1), 15 Detailed reference viewed: 122 (1 ULg)Relationship between changes in bone mineral density and vertebral fracture incidence: an analysis of the last 3 years of an 8-year treatment with strontium ranelateBruyère, Olivier ; Detilleux, Johann ; et alin Osteoporosis International (2009, March), 20(Suppl.1), 11 Detailed reference viewed: 13 (7 ULg)Prevention of falls, bone loss and fractures : D-hormone analogs or native vitamin D? a meta-perspective; ; Reginster, Jean-Yves in Osteoporosis International (2009, March), 20(Suppl.1), 90 Detailed reference viewed: 9 (1 ULg)The antifracture efficacy of ibandronate: a compendium of evidence.Reginster, Jean-Yves in Osteoporosis International (2009, March), 20(Suppl.1), 182-183 Detailed reference viewed: 8 (0 ULg)Effect on single annual infusion of zoledronic acid (5mg) on lumbar spine bone mineral density versus daily oral risedronate (5mg) in subgroups of patients receiving glucocorticoid therapy.; ; et al in Osteoporosis International (2009, March), 20(Suppl.1), 7-8 Detailed reference viewed: 7 (1 ULg)Positive impact of compliance to strontium ranelate on the risk of non-vertebral osteoporotic fracturesRabenda, Véronique ; Reginster, Jean-Yves in Osteoporosis International (2009, March), 20(Suppl.1), 89 Detailed reference viewed: 5 (3 ULg)Relationship between 3-month changes in biochemical markers of bone remodelling and 3-year changes in bone mineral density in patients treated with strontium ranelate.Bruyère, Olivier ; ; Collette, Julien et alin Osteoporosis International (2009, March), 20(Suppl.1), 86-87 Detailed reference viewed: 12 (9 ULg)Association between changes in bone mineral density and fracture incidence in postmenopausal women receiving calcium and vitamin D : A 3-year study.Bruyère, Olivier ; Hiligsmann, Mickaël ; Frankinet, Pierre et alin Osteoporosis International (2009, March), 20(Suppl.1), 87-88 Detailed reference viewed: 17 (11 ULg)Relationship between changes in bone mineral density and compliance to strontium ranelateRabenda, Véronique ; Bruyère, Olivier ; Reginster, Jean-Yves in Osteoporosis International (2009, March), 20(Suppl.1), 152-153 Detailed reference viewed: 8 (6 ULg)Glucosamine sulfate in the treatment of knee osteoarthritis: impact on health utility.; Bruyère, Olivier ; Hiligsmann, Mickaël et alin Osteoporosis International (2009, March), 20(Suppl.1), 149 Detailed reference viewed: 33 (11 ULg)Effect of glucosamine sulfate on health utility data in patients with knee osteoarthritis : reanalysis of two 3-year prospective studies.; Bruyère, Olivier ; Hiligsmann, Mickaël et alin Osteoporosis International (2009, March), 20(Suppl.1), 18 Detailed reference viewed: 27 (5 ULg) Le cas clinique du mois. Osteogenesis imperfectaKaux, Jean-François ; Le Goff, Caroline ; Debray, François-Guillaume et alin Revue Médicale de Liège (2009) We report the case of a young boy who had had multiple bone fractures (more than 10) since the age of 19 months. The father had the same clinical history. The clinical examination was normal for his age ... [more ▼] We report the case of a young boy who had had multiple bone fractures (more than 10) since the age of 19 months. The father had the same clinical history. The clinical examination was normal for his age except blue sclera. The bone densitometry showed a severe osteoporosis for his age. Biological exam swere correct. The genetic exploration revealed mutation of COL1A2 gene. With this clinical history, the diagnosis of Osteogenesis imperfecta (OI) was retained. OI is a hereditary dystrophy with abnormal synthesis or metabolism of collagen with, often, mutation of COL1A1 or COL1A2 genes. There are 7 different forms. We consider the possible differential diagnoses. The goal of any treatment is to promote bone remineralisation and to decrease the fracture frequency. The treatment includes calcium and vitamin D, and in the presence of some precise criteria, biphosphonate therapy. [less ▲] Detailed reference viewed: 139 (47 ULg) |
||
